NASHUA, N.H., April 28, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it has acquired the M-Vu® Breast Density software from VuCOMP, Inc. Under the terms of the agreement, iCAD acquired the breast density intellectual property product, which will be integrated with iCAD's PowerLook Advanced Mammography Platform (AMP). PowerLook AMP, iCAD's flagship product, is a modular solution designed to provide advanced tools for breast disease detection and analysis, including CAD for tomosynthesis.
Clinical studies have shown that dense breasts can make cancer detection in a mammogram more difficult by potentially masking malignant masses. The acquired breast density tool automatically and rapidly assesses breast density by analyzing the structure, texture and dispersion of the tissue, using the same approach used by many experienced radiologists. Areas with a dense appearance that could hide cancer are quantified into categories established by the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS®). As the need for tailored breast screening protocols grows, automated breast density software will continue to drive an increase in the utilization of breast tomosynthesis.
"We are committed to delivering the innovative cancer detection and radiation therapy solutions that help clinicians find and treat cancers earlier and faster," said Ken Ferry, CEO of iCAD. "We believe that the acquisition of this breast density software is a highly synergistic addition to our product portfolio, expanding the breast density solutions available in PowerLook AMP for the varying needs of our customers."
"With the expanding focus on the use of additional screening, including breast tomosynthesis, we believe automated breast density tools represent an important advantage for radiologists who need fast, accurate assessments of breast density," Mr. Ferry added. "This acquisition is another reflection of iCAD's commitment to being the leader in innovation and service in the digital mammography CAD market in the years ahead."
Legislation has been passed in 22 states requiring physicians to notify patients of their breast density. Patients with dense breast tissue may be recommended for additional screening exams including use of breast tomosynthesis. The availability of more accurate information about breast density can help radiologists better identify women who might benefit for more advanced screening options.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
SOURCE iCAD, Inc.